DTx Pharma, Inc. is a privately held biotechnology company based in San Diego, California, that addresses the challenges associated with delivering RNA-based therapeutics.
Subscribe to see DTx Pharma, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
DTx Pharma, LLC is a life sciences (therapeutics) company headquartered in San Diego, United States. Its most recent funding round, Series B, raised $100.2M in February 2021. Xcout tracks 26 named people at DTx Pharma, LLC, including Vasant (Vas) Narasimhan (Vasant (Vas) Narasimhan).
As of 16 November 2026. Source: Xcout Intel.
20 more named people on record for DTx Pharma, LLC, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $100.2M | 14 named | |
| SEC Form D filing | $200,000 | — | |
| Series A | $10.6M | 3 named | |
| SEC Form D filing | $12M | — | |
| SEC Form D filing | $1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 15 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of DTx Pharma, LLC's closest competitors — see the full list of competitors and alternatives →
Cellics Therapeutics, Inc. is a privately held biotechnology company headquartered in San Diego, California, developing novel therapeutic products.
Creyon Bio is a biotechnology organization that engineers RNA-based and oligonucleotide medicines designed to enable tissue-specific delivery with improved safety and efficacy.
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Defence Therapeutics is a publicly traded Canadian biotechnology company headquartered in Montreal, Quebec. It is a precision intracellular drug-delivery company focused on unlocking the full potential of cancer biologics.
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company located in San Diego, California, focused on turning scientific research into life-saving treatments.
Abilita Therapeutics, Inc. is a privately held biotechnology company founded in 2014 and focused on redefining therapeutics. The company is headquartered in San Diego, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about DTx Pharma, LLC? Suggest a correction · Work at DTx Pharma, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.